Skip to main content

Table 1 Clinical characteristics of patients

From: Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions

 

19ins (N = 83)

Age at diagnosis

 ≤ 56

39 (47.0%)

 > 56

39 (47.0%)

 Unknown

5 (6.0%)

Median (range)

56 (26–81)

Sex

 Female

45 (54.2%)

 Male

38 (45.8%)

Histology type

 LUAD

83 (100%)

Stage of diagnosis

 I–III

18 (21.7%)

 IV

35 (42.2%)

 Unknown

30 (36.1%)

EGFR 19ins

 I740_K745dup

72 (86.7%)

 K745_E746insVPVAIK

11 (13.3%)